A Multicenter, Randomized, Double-dummy, Double-blind Study Evaluating Two Doses of Adalimumab Versus Methotrexate (MTX) in Pediatric Subjects With Chronic Plaque Psoriasis (Ps).

Trial Profile

A Multicenter, Randomized, Double-dummy, Double-blind Study Evaluating Two Doses of Adalimumab Versus Methotrexate (MTX) in Pediatric Subjects With Chronic Plaque Psoriasis (Ps).

Completed
Phase of Trial: Phase III

Latest Information Update: 18 May 2017

At a glance

  • Drugs Adalimumab (Primary) ; Methotrexate
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 18 May 2017 Results published in the Lancet.
    • 04 May 2017 Primary endpoint Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 75 Response at Week 16- for adalimumab 0.8 mg/kg and methotrexate group) has bben met, according to the results published in the Lancet.
    • 04 May 2017 Primary endpoint (Percentage of Participants Achieving a Physicians Global Assessment of Disease Activity (PGA) of Cleared (0) or Minimal (1) at Week 16- for adalimumab 08 mg/kg and methotrexate group) has not been met, according to the Results published in the Lancet.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top